Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of MRSA infections
3.2.1.2 Growing antibiotic resistance
3.2.1.3 Advancements in drug development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of therapeutics
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Glycopeptides
5.3 Lipopeptides
5.4 Oxazolidinones
5.5 Cephalosporin
5.6 Tetracycline
5.7 Folate antagonist
5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By MRSA Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospital-acquired (HA-MRSA)
6.3 Community-acquired (CA-MRSA)
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Skin and soft tissue infections
8.3 Bone & joint infections
8.4 Respiratory infections
8.5 Bacteremia
8.6 Other indications
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Basilea Pharmaceutica Ltd
11.3 Baxter International Inc.
11.4 Cumberland Pharmaceuticals Inc.
11.5 GlaxoSmithKline plc.
11.6 Johnson & Johnson
11.7 Merck & Co., Inc.
11.8 Novartis AG
11.9 Pfizer Inc.
11.10 Teva Pharmaceutical Industries Ltd.
